(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. We
then submitted the isolated RNA samples to the Vanderbilt University Medical
Center VANTAGE Core (Nashville, TN), which performed RNA quality determination
and sequencing according to the following protocol: 1) assess
total RNA quality using a 2100 Bioanalyzer (Agilent, Santa Clara, CA);
2) use at least 200 ng of DNase-treated total RNA with high
integrity to generate poly-A-enriched mRNA libraries, using KAPA Stranded mRNA
sample kits with indexed adaptors (Roche, Indianapolis, IN); 3)
assess library quality using the 2100 Bioanalyzer (Agilent) and quantitate
libraries using KAPA library Quantification kits (Roche); 4)
subject pooled libraries to 150-bp double-end sequencing with the Illumina
NovaSeq600 system (Illumina, San Diego, CA) according to the
manufacturer’s protocol; and 5) use the Bcl2fastq2
Conversion Software v2.20 (Illumina) to generate de-multiplexed Fastq files.